426 related articles for article (PubMed ID: 20160168)
1. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic review of erlotinib in non-small-cell lung cancer.
Yeung K; Carlson JJ
Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):411-23. PubMed ID: 22971028
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib for the treatment of relapsed non-small cell lung cancer.
McLeod C; Bagust A; Boland A; Hockenhull J; Dundar Y; Proudlove C; Davis H; Green J; Macbeth F; Stevenson J; Walley T; Dickson R
Health Technol Assess; 2009 Jun; 13 Suppl 1():41-7. PubMed ID: 19567213
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
6. Economics and the new generation of targeted therapies for non-small cell lung cancer.
Ramsey SD
J Natl Cancer Inst; 2010 Mar; 102(5):287-8. PubMed ID: 20160167
[No Abstract] [Full Text] [Related]
7. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
Cromwell I; van der Hoek K; Malfair Taylor SC; Melosky B; Peacock S
Lung Cancer; 2012 Jun; 76(3):472-7. PubMed ID: 22226627
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence.
Carlson JJ
Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):409-16. PubMed ID: 19817524
[TBL] [Abstract][Full Text] [Related]
11. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
Lee VW; Schwander B; Lee VH
Hong Kong Med J; 2014 Jun; 20(3):178-86. PubMed ID: 24281768
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.
Borget I; Cadranel J; Pignon JP; Quoix E; Coudert B; Westeel V; Dansin E; Madelaine J; Madroszyk A; Friard S; Daniel C; Morin F; Chouaid C;
Eur Respir J; 2012 Jan; 39(1):172-9. PubMed ID: 21659409
[TBL] [Abstract][Full Text] [Related]
15. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
[TBL] [Abstract][Full Text] [Related]
16. Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis.
Bajaj PS; Veenstra DL; Goertz HP; Carlson JJ
J Med Econ; 2014 Aug; 17(8):538-46. PubMed ID: 24716717
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Wheatley-Price P; Ding K; Seymour L; Clark GM; Shepherd FA
J Clin Oncol; 2008 May; 26(14):2350-7. PubMed ID: 18467727
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
20. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Bezjak A; Tu D; Seymour L; Clark G; Trajkovic A; Zukin M; Ayoub J; Lago S; de Albuquerque Ribeiro R; Gerogianni A; Cyjon A; Noble J; Laberge F; Chan RT; Fenton D; von Pawel J; Reck M; Shepherd FA;
J Clin Oncol; 2006 Aug; 24(24):3831-7. PubMed ID: 16921034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
